ECE2024 Poster Presentations Adrenal and Cardiovascular Endocrinology (95 abstracts)
Evaluation of quality of life by AddiQoL-30 compared to SF-36 in patients with previous long-term prednisolone treatment
Hajir Al-Jorani 1,2 , Stina Willemoes Borresen 3 , Lise Sofie Bislev 4,5 , Richard Christian Jensen 1 , Anja Fenger Dreyer 1,2 , Simon Bøggild Hansen 4,5 , Victor Brun Boesen 3 , Louise Lehmann Christensen 1,2 , Dorte Glintborg 1,2 , Nanna Thurmann Jørgensen 3,6 , Marianne Klose 3 , Marie Louise Lund 3,6 , Jelena Stankovic 4,5 , Randi Tei 4,5 , Ulla Feldt-Rasmussen 3,6 , Jens Otto Jørgensen 4,5 & Marianne Andersen 1,2
1Odense University Hospital, Department of Endocrinology, Odense, Denmark; 2Research Unit OPEN, University of Southern Denmark, Department of Clinical Research, Odense, Denmark; 3Copenhagen University Hospital, Rigshospitalet, Department of Endocrinology and Metabolism, Copenhagen, Denmark; 4Aarhus University, Department of Clinical Medicine, Aarhus, Denmark; 5Aarhus University Hospital, Department of Endocrinology and Internal Medicine, Aarhus, Denmark; 6Faculty of Health and Clinical Sciences, Copenhagen University, Department of Clinical Medicine, Copenhagen, Denmark
Background: Long-term prednisolone therapy may lead to subtle changes in circadian oscillations of the hypothalamic-pituitary-adrenal axis, which can affect quality of life of the patient. Low score of the Addison’s disease-specific quality-of-life questionnaire (AddiQoL-30) could be a method to assess functional glucocorticoid-induced adrenal insufficiency.
Objective: To compare scores from AddiQoL-30 with generic Short Form (SF-36) questionnaire in patients terminating long-term prednisolone therapy.
Methods: This study is part of REPLACE, an ongoing multicenter, randomized, double-blinded placebo-controlled study, and sub-study of The Double Edge Study. We included 140 patients (72 women) with median age of 73 years, diagnosed with polymyalgia rheumatica and/or giant cell arteritis, where prednisolone was terminated during 2–12 weeks. AddiQoL-30 and SF-36 questionnaires as well as a clinical examination were carried out, and baseline standardized fasting cortisol levels were assessed. Multiple linear regression models were used to evaluate associations between AddiQoL-30 and SF-36.
Results: Patients with low AddiQoL-30 scores (≤85) had significantly lower baseline cortisol levels (P=0.03) (abstract ID: 5059). In patients with low AddiQoL-30 scores, baseline cortisol showed positive association with the four SF-36 domains vitality, role limitations physical, social and physical functioning. The estimate for vitality in patients with AddiQoL-30 scores ≤85 was significantly different from patients with AddiQoL-30 scores >85 (P-interaction=0.01). In patients with AddiQoL-30 scores >85, associations between SF-36 and cortisol were not significant.
Conclusion: A low AddiQoL-30 score ≤85 may align with the SF-36, especially regarding the vitality dimension, in patients with previous long-term prednisolone use. The REPLACE sub-study (abstract ID: 4814) is still recruiting, and baseline and follow-up investigations of AddiQoL-30 and SF-36 questionnaires are ongoing.
Funding: The Double Edge Study is funded by the Novo Nordisk Foundation as part of a collaborative grant entitled ‘double edge – Characterization and mitigation of adverse effects of glucocorticoid treatment’ (NNF20OC0063280).
Disclosure of interest: None declared.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more